Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.
|Articles|February 1, 2010
Drug Topics, Digital Edition, February 2010
Part 2 Pipeline Drugs 2010 : What the future holds New developments in diabetes management Financial checkup for pharmacies No magic bullet for MRSA SSIs
Advertisement
Advertisement
Related to this article
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Kimberly Kue-Tsemo, PharmD, explores the current state of US pharmacy deserts amid ongoing reform, evolution in practice, and more.
Alyssa Eisenberg, PharmD, discusses key industry challenges and developments as community pharmacists continue to impact patient outcomes across the US.
Allison Schneider, MPH, provides expertise on how IRA drug price negotiations have impacted pharmacies in 2026 and what’s to come in the years ahead.
Shantel Upshaw Houston shares tips to prevent burnout, explains how pharmacists fill gaps in care, and urges midcareer peers to mentor students.
Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
2
No Added Adverse Event Risk in Pfizer-BioNTech COVID-19 Vaccine
3
Future IRA Drug Negotiations Expected to Compound Pharmacy Burden
4
American Pharmacists Month: Pharmacists’ Ability to Expand Community Impact
5